Results of imatinib therapy for metastatic gastrointestinal stromal tumor

Trial	Phase	Number of patients	Dose in, mg/day	Follow-up, months	Best response, percent
					CR	PR	SD	PFS, months
US Multicenter Blanke, C; 2008	II	73	400	63	-	61	16	20*
		74	600		3	65		26*
EORTC Verweij, J; 2004	III	470	400	25	5	45	32	2-year PFS 50%
		472	800					2-year PFS 56%
US Intergroup Blanke, C; 2008	III	361	400	54	-	43	32	18
		360	800					20

* Median time to tumor progression (TTP) in months.

CR: complete response; PR: partial response; SD: stable disease; PFS: progression-free survival; EORTC: European Organization for the Research and Treatment of Cancer.

Graphic 78415 Version 2.0